All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
An oral session on lymphoma took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 19 March 2018. Abstract OS1-8 was presented by Herbert G. Sayer, chief doctor at the Helios Hospital Erfurt, Germany on the use of thiotepa-based autologous stem cell transplantation (ASCT) in primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL), and non-CNS lymphoma.
Dr. Sayer concluded that these early study results demonstrated promise for thiotepa-based HDC in terms of efficacy for CNS and non-CNS lymphoma with an acceptable safety profile.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox